Illumina, Inc. reported preliminary non‑GAAP diluted earnings per share of $1.27 to $1.30 for the fourth quarter of fiscal 2025, and $4.76 to $4.79 for the full year, both exceeding analyst consensus estimates of $1.21 and $4.70 respectively. The company also posted preliminary revenue of $1.155 billion for the quarter and $4.34 billion for the year, beating consensus estimates of $1.10 billion and $4.28 billion.
Revenue grew 5% from $1.10 billion in Q4 2024 and 4% on a constant‑currency basis, driven by robust demand outside of China. The company’s focus on expanding its market presence beyond China, combined with a higher mix of consumables and services, helped offset the slowdown in its core instrument sales in the Chinese market.
Segment‑level analysis shows that consumables and services revenue increased by 7% YoY, while instrument revenue remained flat at $1.02 billion. The shift toward higher‑margin consumables and services contributed to the overall earnings beat, as the company maintained disciplined cost management and leveraged its global supply chain.
Operating margin for the quarter was 21.3%, a slight improvement over the 21.0% margin reported in Q4 2024, reflecting effective cost controls and a favorable product mix. The EPS beat was largely driven by the higher margin mix and the absence of significant one‑time charges, allowing the company to translate revenue growth into earnings growth.
In a statement, Illumina’s management emphasized the company’s resilience and its strategic focus on expanding outside China. The leadership highlighted the ongoing SomaLogic acquisition as a key driver of future growth, noting that the integration will broaden Illumina’s proteomics portfolio and strengthen its competitive position in the life‑science market.
Analysts noted that the earnings beat and revenue growth signal strong execution and a solid demand trajectory, particularly in the U.S. and European markets. The company’s guidance for the remainder of fiscal 2025 remains unchanged, underscoring management’s confidence in sustaining growth momentum.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.